Douglas T. Dieterich mainly focuses on Internal medicine, Immunology, Hepatitis C virus, Ribavirin and Hepatitis C. As part of the same scientific family, Douglas T. Dieterich usually focuses on Internal medicine, concentrating on Gastroenterology and intersecting with Liver biopsy. His Immunology research includes elements of Clinical trial and Risk factor.
Douglas T. Dieterich studies Hepatitis C virus, namely Sofosbuvir. Ribavirin is a subfield of Virology that Douglas T. Dieterich investigates. His Hepatitis C study combines topics from a wide range of disciplines, such as Pharmacotherapy, Adverse effect, Acquired immunodeficiency syndrome and Viral load.
His main research concerns Internal medicine, Hepatitis C virus, Virology, Ribavirin and Hepatitis C. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Viral load, Immunology and Sofosbuvir. As part of one scientific family, Douglas T. Dieterich deals mainly with the area of Hepatitis C virus, narrowing it down to issues related to the Cirrhosis, and often Fibrosis.
His work in the fields of Virology, such as Virus, Faldaprevir, Hepatitis B virus and Interferon, intersects with other areas such as In patient. His Ribavirin research incorporates themes from Regimen, Adverse effect and Alpha interferon. His Hepatitis C research is multidisciplinary, incorporating elements of Direct acting, Surgery, Pharmacology and Hepatitis.
His primary areas of study are Internal medicine, Hepatitis C, Hepatitis C virus, Virology and Gastroenterology. His Internal medicine study incorporates themes from Surgery, Oncology and Ribavirin, Genotype, Sofosbuvir. His research on Hepatitis C also deals with topics like
His studies in Hepatitis C virus integrate themes in fields like Interquartile range, Viral load, Hepatocellular carcinoma, Prospective cohort study and Drug. In general Virology study, his work on Telaprevir and Virus often relates to the realm of In patient, thereby connecting several areas of interest. Douglas T. Dieterich has researched Gastroenterology in several fields, including Nonalcoholic fatty liver disease and Liver transplantation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen.
The New England Journal of Medicine (2004)
Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study
Naga Chalasani;Herbert L. Bonkovsky;Robert Fontana;William Lee.
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie;Curtis Cooper;Michael Saag;Kimberly Workowski.
The New England Journal of Medicine (2015)
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
David L. Wyles;Peter J. Ruane;Mark S. Sulkowski;Douglas Dieterich.
The New England Journal of Medicine (2015)
A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
Mark G. Swain;Ming–Yang Lai;Mitchell L. Shiffman;W. Graham E. Cooksley.
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.
Emmet B. Keeffe;Stefan Zeuzem;Raymond S. Koff;Douglas T. Dieterich.
Clinical Gastroenterology and Hepatology (2007)
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Nezam H. Afdhal;Douglas T. Dieterich;Paul J. Pockros;Eugene R. Schiff.
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Vincent Soriano;Mark Sulkowski;Colm Bergin;Angelos Hatzakis.
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Mark S. Sulkowski;Susanna Naggie;Jacob Lalezari;Walford Jeffrey Fessel.
Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies
Paul A. Volberding;Alexandra M. Levine;Douglas Dieterich;Donna Mildvan.
Clinical Infectious Diseases (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: